21 results on '"Meltem Kurt Yüksel"'
Search Results
2. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data
- Author
-
Ekin Kırcalı, Güldane Cengiz Seval, Cemaleddin Öztürk, Hülya Yılmaz, Derya Koyun, Sinem Civriz Bozdağ, Selami Koçak Toprak, Pervin Topçuoğlu, Önder Arslan, Muhit Özcan, Taner Demirer, Osman İlhan, Günhan Gürman, Meral Beksaç, and Meltem Kurt Yüksel
- Subjects
Medicine - Abstract
Background: Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia. Aims: To present our centre’s experience of using this agent not only for post- haematopoietic cell transplantation thrombocytopaenia but also for poor graft functioning in the post-haematopoietic cell transplantation setting. Study Design: Retrospective cross-sectional study. Methods: Thirty-nine patients who had persistent cytopaenia following haematopoietic cell transplantation and treated with eltrombopag at our centre between October 2011 and December 2021 were retrospectively identified. During this period, 9 (23.1%) and 30 (76.9%) patients who underwent allogeneic transplantations, respectively, received eltrombopag. Results: The female-to-male ratio was 12:27, and the median transplant age was 49 (18-70) years. Eight (20.5%) patients had isolated thrombocytopaenia, 19 (49.4%) had bi-lineage cytopaenia and 12 (30.1%) had pancytopaenia. Patients received a median of 50 mg/day (25-150 mg/day) of eltrombopagfor a median duration of 82 (24-386) days. Nine (23.1%) patients had autologous haematopoietic cell transplantation, and 30 (76.9%) had allogeneic haematopoietic cell transplantation (14 unrelated, 9 sibling and 7 haploidentical). The median donor age was 32 (20-67) years. The median follow-up was 16.4 (1.8-84.3) months. The median pre-treatment platelet count was 11x109/l (1-23), which increased to 41x109/l (6-150). The median platelet count increment was 29.5x109/l (p = 0.001). The pre-treatment median neutrophil count was 1.19x109/l (0.39-5.1), which increased to 2.35 x109/l (0.1-5.33) (p = 0.05), and the pre-treatment median haemoglobin was 8.3 (6.2-14) g/dl, which increased to 10 (6.2-14) g/dl (p = 0.001) with eltrombopag. No eltrombopag-related hepatotoxicity occurred; however, 1 (2.6%) patient failed to continue treatment because of two consecutive episodes of deep venous thrombosis. Six (15.4%) patients were unresponsive to eltrombopag and dependent on blood product transfusions. After a median time of 82 days, 61.5% of the patients discontinued eltrombopag successfully. Conclusion: The results confirmed that eltrombopag could provide a rapid, sustained response in patients with poor graft functioning after haematopoietic cell transplantation. This finding is essential given the high rate of non-relapse mortality caused by poor graft functioning after haematopoietic cell transplantation.
- Published
- 2023
- Full Text
- View/download PDF
3. P1686: LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY
- Author
-
Fabio Efficace, Laura Cannella, Xavier Thomas, Meltem Kurt Yüksel, Silvia Maria Trisolini, Alberto Brini, Ernesta Audisio, Luca Maurillo, Roberto M. Lemoli, Annalisa Imovilli, Irina Panovska-Stavridis, Livio Pagano, Maria Ciccone, Nunzio Filardi, Nicola Stefano Fracchiolla, Daniele Vallisa, Monica Crugnola, Nicola Cascavilla, Matevz Skerget, Marco Vignetti, Frederic Baron, and On Behalf of the Gimema and Eortc Leukemia and Quality of Life Groups
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
4. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
- Author
-
Per Ljungman, Gloria Tridello, Jose Luis Piñana, Fabio Ciceri, Henrik Sengeloev, Alexander Kulagin, Stephan Mielke, Zeynep Arzu Yegin, Matthew Collin, Sigrun Einardottir, Sophie Ducastelle Lepretre, Johan Maertens, Antonio Campos, Elisabetta Metafuni, Herbert Pichler, Frantisek Folber, Carlos Solano, Emma Nicholson, Meltem Kurt Yüksel, Kristina Carlson, Beatriz Aguado, Caroline Besley, Jenny Byrne, Immaculada Heras, Fiona Dignan, Nicolaus Kröger, Christine Robin, Anjum Khan, Stig Lenhoff, Anna Grassi, Veronika Dobsinska, Nuno Miranda, Maria-Jose Jimenez, Ipek Yonal-Hindilerden, Keith Wilson, Dina Averbuch, Simone Cesaro, Alienor Xhaard, Nina Knelange, Jan Styczynski, Malgorzata Mikulska, and Rafael de la Camara
- Subjects
COVID-19 ,allogeneic ,stem cell transplantation ,CMV ,risk factors ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionCOVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.MethodsThis study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic.ResultsThe median age was 50.3 years (min – max; 1.0 – 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min – max; 0.0 – 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 – 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p
- Published
- 2023
- Full Text
- View/download PDF
5. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
- Author
-
Sinem Civriz Bozdağ, Güldane Cengiz Seval, İpek Yönal Hindilerden, Fehmi Hindilerden, Neslihan Andıç, Mustafa Baydar, Lale Aydın Kaynar, Selami Koçak Toprak, Hasan Sami Göksoy, Berrin Balık Aydın, Ufuk Demirci, Ferda Can, Vildan Özkocaman, Eren Gündüz, Zeynep Tuğba Güven, Zübeyde Nur Özkurt, Sinan Demircioğlu, Meral Beksaç, İdris İnce, Umut Yılmaz, Hilal Eroğlu Küçükdiler, Elgün Abishov, Boran Yavuz, Ünal Ataş, Yaşa Gül Mutlu, Volkan Baş, Fahir Özkalemkaş, Hava Üsküdar Teke, Vildan Gürsoy, Serhat Çelik, Rafiye Çiftçiler, Münci Yağcı, Pervin Topçuoğlu, Özcan Çeneli, Hamza Abbasov, Cem Selim, Muhlis Cem Ar, Orhan Kemal Yücel, Sevil Sadri, Canan Albayrak, Ahmet Muzaffer Demir, Nil Güler, Muzaffer Keklik, Hatice Terzi, Ali Doğan, Zeynep Arzu Yegin, Meltem Kurt Yüksel, Soğol Sadri, İrfan Yavaşoğlu, Hüseyin Saffet Beköz, Tekin Aksu, Senem Maral, Veysel Erol, Leylagül Kaynar, Osman İlhan, Ali Zahit Bolaman, Ömür Gökmen Sevindik, Arzu Akyay, Muhit Özcan, Günhan Gürman, Şule Ünal, Yasemin Yavuz, Reyhan Diz Küçükkaya, and Güner Hayri Özsan
- Subjects
covid-19 ,sars-cov-2 enfeksiyon ,hematolojik malignite ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV- 2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
- Published
- 2022
- Full Text
- View/download PDF
6. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors
- Author
-
Zehra Narlı Özdemir, Uğur Şahin, Klara Dalva, Mehmet Akif Baltacı, Atilla Uslu, Cemaleddin Öztürk, Güldane Cengiz Seval, Selami Koçak Toprak, Meltem Kurt Yüksel, Pervin Topçuoğlu, Önder Arslan, Muhit Özcan, Meral Beksaç, Osman İlhan, Günhan Gürman, and Sinem Civriz Bozdağ
- Subjects
acute myeloid leukemia ,measurable residual disease ,multiparameter flow cytometry ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: The optimal timing of measurable residual disease (MRD) evaluation in acute myeloid leukemia (AML) patients has not been well defined yet. We aimed to investigate the impact of MRD in pre- and post-allogeneic hematopoietic stem cell transplantation (AHSCT) periods on prognostic parameters. Materials and Methods: Seventy-seven AML patients who underwent AHSCT in complete morphological remission were included. MRD analyses were performed by 10-color MFC and 10-4 was defined as positive. Relapse risk and survival outcomes were assessed based on pre- and post-AHSCT MRD positivity. Results: The median age of the patients was 46 (range: 18-71) years, and 41 (53.2%) were male while 36 (46.8%) were female. The median follow-up after AHSCT was 12.2 months (range: 0.2-73.0). The 2-year overall survival (OS) in the entire cohort was 37.0%, with a significant difference between patients who were MRD-negative and MRD-positive before AHSCT, estimated as 63.0% versus 16.0%, respectively (p=0.005). MRD positivity at +28 days after AHSCT was also associated with significantly inferior 2-year OS when compared to MRD negativity (p=0.03). The risk of relapse at 1 year was 2.4 times higher (95% confidence interval: 1.1-5.6; p=0.04) in the pre-AHSCT MRD-positive group when compared to the MRD-negative group regardless of other transplant-related factors, including pre-AHSCT disease status (i.e., complete remission 1 and 2). Event-free survival (EFS) was significantly shorter in patients who were pre-AHSCT MRD-positive (p=0.016). Post-AHSCT MRD positivity was also related to an increased relapse risk. OS and EFS were significantly inferior among MRD-positive patients at +28 days after AHSCT (p=0.03 and p=0.019). Conclusion: Our results indicate the importance of MRD before and after AHSCT independently of other factors
- Published
- 2021
- Full Text
- View/download PDF
7. Secondary Infections in Cancer Patients with Febrile Neutropenia
- Author
-
Alpay Azap, Gülden Yılmaz Bozkurt, Meltem Kurt Yüksel, Hakan Kutlu, Pervin Topçuoğlu, Adalet Aypak, and Hamdi Akan
- Subjects
hematologic malignancy ,febrile neutropenia ,secondary infection ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
OBJECTIVE: Patients with neutropenia due to cancer chemotherapy are prone to severe infections. Cancer patients can experience >1 infectious episode during the same period of neutropenia. This study aimed to determine the etiological and clinical characteristics of secondary infectious episodes in cancer patients with febrile neutropenia and to identify the factors associated with the risk of secondary infectious episodes. METHODS: All cancer patients that received antineoplastic chemotherapy at Ankara University, School of Medicine, Department of Hematology between May 2004 and May 2005 and developed neutropenia were included in the study. Data were collected using survey forms that were completed during routine infectious diseases consultation visits. Categorical data were analyzed using the chi-square test, whereas Student's t-test was used for continuous variables. Multivariate logistic regression analysis was performed to identify independent predictors of secondary infections (SIs). RESULTS: SIs were observed during 138 (53%) of 259 febrile neutropenic episodes. Of the 138 episodes, 89 (64.5%) occurred in male patients with a mean age of 40.9 years (range: 17-76 years). In total, 80% of the SIs were clinically or microbiologically documented. Factors on d 4 of the initial febrile episode were analyzed via a logistic regression model. The presence of a central intravenous catheter (OR: 3.01; P < 0.001), acute myeloid leukemia (AML) as the underlying disease (OR: 2.12; P = 0.008), diarrhea (OR: 4.59; P = 0.005), and invasive aspergillosis (IA) during the initial febrile episode (OR: 3.96; P = 0.009) were statistically significant risk factors for SIs. CONCLUSION: Among the cancer patients with neutropenia in the present study, AML as the underlying disease, the presence of a central venous catheter, diarrhea, and IA during the initial febrile episode were risk factors for the development of SIs.
- Published
- 2012
- Full Text
- View/download PDF
8. Paclitaxel therapy and immune thrombocytopenic purpura: Coincidence or association?
- Author
-
Ümmügül Üyetürk, Şerife Hülya Arslan, Meltem Kurt Yüksel, and Fevzi Altuntaş
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2011
9. The Relation of Hepcidin, Vitamin D and Inflammatory Parameters, and Effects on Intensive Care Unit Outcome in Critically Ill COVID-19 Patients
- Author
-
Leyla Ferliçolak, Nur Seren Bildiren, Özlem Doğan, Merve Yüksel, Meltem Kurt Yüksel, and Neriman Defne Altıntaş
- Subjects
General Medicine - Published
- 2023
10. Evaluation of the Distribution and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Blood Cultures in Heamatologic Febrile Neutropenia Attacks
- Author
-
Güle Çınar, Duygu Öcal, Güldane Cengiz Seval, İrem Akdemir Kalkan, Ezgi Gülten, Elif Mukime Sarıcaoğlu, Haluk Güriz, Sinem Civriz Bozdağ, Selami Koçak Toprak, Meltem Kurt Yüksel, and Alpay Azap
- Subjects
General Medicine - Published
- 2022
11. İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi
- Author
-
Ekin Kırcalı, Güldane Cengiz Seval, Cemaleddin Öztürk, Hülya Yılmaz, Mustafa Can Şenoymak, Gül Yavuz Ermiş, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Pervin Topçuoğlu, Önder Arslan, Taner Demirer, Osman İlhan, Günhan Gürman, Meral Beksaç, and Selami Koçak Toprak
- Published
- 2022
12. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data
- Author
-
Ekin Kırcalı, Güldane Cengiz Seval, Cemaleddin Öztürk, Hülya Yılmaz, Derya Koyun, Sinem Civriz Bozdağ, Selami Koçak Toprak, Pervin Topçuoğlu, Önder Arslan, Muhit Özcan, Taner Demirer, Osman İlhan, Günhan Gürman, Meral Beksaç, and Meltem Kurt Yüksel
- Subjects
General Medicine - Abstract
Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia.To present our centre's experience of using this agent not only for post- haematopoietic cell transplantation thrombocytopaenia but also for poor graft functioning in the post-haematopoietic cell transplantation setting.Retrospective cross-sectional study.Thirty-nine patients who had persistent cytopaenia following haematopoietic cell transplantation and treated with eltrombopag at our centre between October 2011 and December 2021 were retrospectively identified. During this period, 9 (23.1%) and 30 (76.9%) patients who underwent allogeneic transplantations, respectively, received eltrombopag.The female-to-male ratio was 12:27, and the median transplant age was 49 (18-70) years. Eight (20.5%) patients had isolated thrombocytopaenia, 19 (49.4%) had bi-lineage cytopaenia and 12 (30.1%) had pancytopaenia. Patients received a median of 50 mg/day (25-150 mg/day) of eltrombopagfor a median duration of 82 (24-386) days. Nine (23.1%) patients had autologous haematopoietic cell transplantation, and 30 (76.9%) had allogeneic haematopoietic cell transplantation (14 unrelated, 9 sibling and 7 haploidentical). The median donor age was 32 (20-67) years. The median follow-up was 16.4 (1.8-84.3) months. The median pre-treatment platelet count was 11x10The results confirmed that eltrombopag could provide a rapid, sustained response in patients with poor graft functioning after haematopoietic cell transplantation. This finding is essential given the high rate of non-relapse mortality caused by poor graft functioning after haematopoietic cell transplantation.
- Published
- 2022
13. Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data
- Author
-
Ekin Kırcalı, Güldane Cengiz Seval, Sinem Civriz Bozdağ, Selami Koçak Toprak, Meltem Kurt Yüksel, Önder Arslan, Muhit Özcan, Taner Demirer, Günhan Gürman, Osman İlhan, Hamdi Akan, Meral Beksaç, and Pervin Topçuoğlu
- Abstract
Introduction and Aim: Generic imatinib formulations are increasingly being used as more affordable alternatives worldwide and a few studies have evaluated the safety and efficacy of these. We have retrospectively analyzed our chronic-phase chronic myeloid leukemia (CP- CML) cohort in terms of first-line treatment with Glivec versus generic imatinib. This study aims to evaluate the safety and efficacy of generic imatinib products in CP- CML as the first-line treatment. Material and Method: We retrospectively analyzed our CP- CML cohort from January 2000 to December 2020 treated with either Glivec or one of the generic imatinib formulations. All our patients were followed in accordance with European Leukemia Net (ELN) 2020 recommendations and national hematology association CML guidelines and response definitions were applied according to ELN 2020 criteria. Event-free survival (EFS) was defined as the time between treatment initiation and either loss of hematological response, progression to accelerated phase (AP) or blastic phase (BP), or an adverse effect severer than grade 1. Overall survival (OS) was defined as the time between treatment initiation and death, while on imatinib. For statistical analyses, SPSS version 21.0 was used. All p values < 0.05 were considered statistically significant. Results: A total of 307 patients were analyzed comparing 186 (60.6 %) patients on Glivec (original imatinib) with 121 patients on (39.4 %) generic formulations. 146 (47.6 %) were females. The median age was 46 years (18-88) for Glivec and 51 years (20-79 years) for the generics group (p=0.01). Risk stratifications according to Sokal, Hasford, and ELTS scores were run for both Glivec and generic formulation groups. There was no statistically significant difference in the gender distribution, Sokal, Hasford, ELTS and ECOG scores between the two groups. The median time from the diagnosis to initiate imatinib treatment was 23.5 (1- 156) days for Glivec group and 13 (1- 51) days for the generic group (p< 0.05). But the late onset of the treatment was not associated with treatment failure or death within the Glivec group. The median follow-up was 139 (15- 321.1) months for the Glivec group and 59 (15.9- 171.9) months for generic imatinib groups, respectively (p< 0.05). This difference might be explained by the fact that Glivec has been on the market for about two decades. Similar rates of grade > 1 hematological and non-hematological toxicities were seen in Glivec (n= 17, 9.1 %) and generics group (n= 9, 7.4 %), respectively (p= 0.382). Optimal molecular response rate (OMRR) at 3 months was 77.9 % (n= 113) for Glivec and 43.8 % (n= 53) for generics group (p< 0.001). Similarly, the OMRR at 6 and 12 months was significantly higher in original imatinib group. Median EFS was found significantly higher for Glivec group compared to the generic group (97.5 months (95% CI: 159-177) vs 46.3 months (95% CI: 56-93); pConclusion: We found that OMRR of Glivec group in early phase of treatment was significantly higher than the generic imatinib group. The generics group presented with a lower OMRR at 3, 6 and 12th months as well as e lower median EFS. No significant difference in safety concerns was observed between the groups. Generic imatinib formulations may yield lower EFS and OMRR when used in first line for CP-CMLç
- Published
- 2022
14. CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study
- Author
-
Ufuk Demirci, Hakkı Onur Kırkızlar, Elif G. Ümit, Vildan Gürsoy, İbrahim Ethem Pınar, Fahir Özkalemkaş, Zeynep Tuğba Güven, Leylagül Kaynar, Fatma Keklik Karadağ, Güray Saydam, Ömer Ekinci, Mustafa Merter, Merih Reis Aras, Murat Albayrak, Sedanur Karaman Gülsaran, Volkan Baş, Berrin Balık Aydın, Hüseyin Saffet Beköz, Ferda Can, İmdat Dilek, Özgür Mehtap, Erman Öztürk, Bengü Çöbanoğlu Şimşek, Murat Yıldırım, Meltem Aylı, Ünal Ataş, Ozan Salim, Mesut Ayer, Elif Birtaş Ateşoğlu, Olga Meltem Akay, Meltem Kurt Yüksel, Semra Paydaş, Selçuk Korkmaz, Fulya Öz Puyan, and Ahmet Muzaffer Demir
- Subjects
Histology ,protein bcl 2 ,overall survival ,very elderly ,interferon regulatory factor 4 ,CD 5 ,protein bcl 6 ,Article ,Pathology and Forensic Medicine ,male ,Double/triple expressor ,human ,fluorescence in situ hybridization ,CD20 antigen ,progression free survival ,cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus rituximab plus vincristine ,ECOG Performance Status ,adult ,lactate dehydrogenase ,Hematology ,Diffuse large B-cell lymphoma ,CNS prophylaxis ,major clinical study ,diffuse large B cell lymphoma ,CD5 antigen ,aged ,c-MYC ,common acute lymphoblastic leukemia antigen ,female ,Myc protein ,CD3 antigen ,Ki 67 antigen ,pathology ,prognosis ,cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine - Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2022
15. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease
- Author
-
Derya Koyun, Güldane Cengiz Seval, Ekin Kırcalı, Sinem Civriz Bozdağ, Selami Koçak Toprak, Pervin Topçuoğlu, Muhit Özcan, Önder Arslan, Taner Demirer, Osman İlhan, Meral Beksaç, Günhan Gürman, and Meltem Kurt Yüksel
- Subjects
Short Communication ,Hematology - Abstract
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, the results of five SR-aGVHD patients received AAT evaluated. Complete response was seen 2 of four patients with gastrointestinal (GI) aGVHD, partial response in one GI and one liver aGVHD. The overall response rate was 80%. AAT is an effective and safe treatment option in SR-aGVHD.
- Published
- 2021
16. Phenotypes of BONE Marrow Monocytes in STEM Cell Transplantation for ACUTE Leukemia: A Descriptive PILOT Study
- Author
-
Meltem Kurt Yüksel, Ekin Kırcalı, Gül Yavuz Ermiş, Guldane Cengiz Seval, Cemaleddin Öztürk, Hülya Yilmaz, Şenay İpek, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Klara Dalva, and Gunhan Gurman
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Published
- 2022
17. Allogeneic Stem Cell Transplantation Experience in Chronic Lymphocytic Leukemia
- Author
-
Erden Atilla, Gültekin Pekcan, Pınar Ataca Atilla, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Selami Koçak Toprak, Pervin Topçuoğlu, Muhit Özcan, Osman İlhan, Günhan Gürman, and Önder Arslan
- Subjects
lcsh:R5-920 ,Chronic Lymphocytic Leukemia ,lcsh:Medicine (General) ,Allogeneic Stem Cell Transplantation - Abstract
Objective:Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. In pa-tients with poor prognosis, allogeneic stem cell transplantation (ASCT) treatment is an alterna-tive. ASCT indications in CLL: Patients with refractory disease or early relapse (shorter than 12 months) after treatment with purine analogues, relapse within 24 months after achieving re-sponse with purine analogues/autologous stem cell transplantation or in patients with p53 anomalies. However, the indications have been revised after novel therapies reached successful results in relapsed/refractory setting. In this study, we aimed to evaluate our CLL patients who underwent ASCT.Materials and Methods:Seven high-risk patients with CLL who were diagnosed at Ankara Uni-versity School of Medicine Department of Hematology between 2007-2015 and subsequently underwent ASCT at our Bone Marrow Transplantation Unit were evaluated retrospectively.Results:In post-transplant disease evaluation, 4/7 patients (57%) achieved complete remission and 3/7 patients (43%) did not respond. Acute graft versus host disease was detected in 2/7 (29%) patients while 3/7 (43%) patients were diagnosed with chronic graft versus host disease. Overall survival was 69 months (range, 19-121 months).Conclusion:Sustained response rates can be achieved with ASCT in high-risk CLL patients in long-term.
- Published
- 2018
18. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center
- Author
-
Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Gunhan Gurman, Meral Beksac, Osman Ilhan, and Muhit Ozcan
- Subjects
Medicine - Abstract
Background: Allogeneic hematopoietic stem cell transplantation is a well-established approach for patients diagnosed with primary myelofibrosis and remains the only potentially curative treatment. Aims: To present the overall outcome of patients with myelofibrosis treated with allogeneic hematopoietic stem cell transplantation. Study Design: A retrospective cross-sectional study Methods: This study is a retrospective analysis of 26 consecutive patients with primary myelofibrosis who underwent transplantation at our center between January 2002 and January 2022. Disease and transplant variables contributing to outcomes were analyzed. Results: The median age at the time of transplantation was 52.5 (range, 32-63) years and the median time from diagnosis to allogeneic hematopoietic stem cell transplantation was 25 (range, 3.1-156.8) months. Myeloablative conditioning and reduced-intensity conditioning regimens were used in 8 (30.8%) and 18 (69.2%) transplantations, respectively. Neutrophil and platelet engraftment was achieved in 23 patients at a median follow-up of 21.2 months (range, 12 days to 234.8 months). Primary graft failure occurred in 1 of 23 patients (4.3%). Neutrophil and platelet engraftment occurred at a median of 16 (range, 12-39) days and 20 (range, 11-78) days, respectively. Acute graft-versus-host disease was seen in 11 of 22 patients engrafted allografts, of which 7 (31.8%) were grade 3-4 acute graft-versus-host disease. Eight patients (36.4%) developed chronic graft-versus-host disease, and three cases were extensive. Four patients (19%) relapsed after a median of 5.5 months, and three patients received donor lymphocyte infusion. The 3-year overall survival rate of the entire study population was 46.2%. The median overall survival was not reached in the myeloablative conditioning group; however, it was 11.9 months in the reduced-intensity conditioning group (p =0.3). According to the donor graft source, the median overall survival was 0.73 months in mismatched unrelated graft recipients, 12 months in matched sibling donors, and not reached in matched unrelated graft recipients (p = 0.03). The 3-year progression-free survival rate of patients who survived > 100 days was 74.7%. The effect of JAK-2 status, graft source, conditioning regimen or dynamic international prognostic scoring system on progression-free survival was not statistically significant. Conclusion: Given the poor prognosis of non-transplant recipients and the lack of non-transplant curative approaches, our results support the consideration of allogeneic hematopoietic stem cell transplantation for eligible patients with primary myelofibrosis.
- Published
- 2023
- Full Text
- View/download PDF
19. Adult Stem Cells and Medicine
- Author
-
Sinem Civriz, Bozdağ, Meltem Kurt, Yüksel, and Taner, Demirer
- Subjects
Adult Stem Cells ,Hematologic Neoplasms ,Hematopoietic Stem Cell Transplantation ,Humans ,Hematopoietic Stem Cells ,Bone Marrow Transplantation - Abstract
Stem cells can be either totipotent, pluripotent, multipotent or unipotent. Totipotent cells have the capability to produce all cell types of the developing organism, including both embryonic and extraembryonic tissues. The Hematopoietic Stem Cells (HSC) are the first defined adult stem cells (ASC) that give rise to all blood cells and immune system. Use of HSCs for treatment of hematologic malignancies, which is also called bone marrow (BM) transplantation or peripheral blood stem cells (PBSC) transplantation is the pioneer of cellular therapy and translational research. However, stem cell research field is developing so fast that, innovative approaches using HSCs for treatment of refractory diseases are growing rapidly. Hematopoietic stem cell transplantation (HSCT) has been widely used to achieve cure in different hematological diseases. Applications include the treatment of marrow failure syndromes, leukemia, lymphoma, multiple myeloma (MM), certain inherited blood disorders, autoimmune diseases and as an enzyme replacement in metabolic disorders. Innovative approaches such as haploidentical stem cell transplantation, new monoclonal antibodies and immunotherapies as well as Chimeric Antigen Receptor T-cell (CAR-T cell) therapies are on the way as promising treatment options especially for patients with refractory hematologic malignancies and even in solid tumors. However, there are still some challenges remaining before some of these therapies are translated into clinical application. In this paper, HSCs including its properties, niches, clinical usage and its contribution to modern medicine today and in the future will be discussed.
- Published
- 2018
20. PB2213: RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE
- Author
-
Hulya Yilmaz, Guldane Cengiz Seval, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Isinsu Kuzu, Meral Beksac, and Muhit Ozcan
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
21. Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Pinar Ataca, Erden Atilla, Pelin Saracoglu, Gulden Yilmaz, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Koray Ceyhan, and Pervin Topcuoglu
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Aspergillus thyroiditis is a rare disorder detected in immunocompromised patients during disseminated infections. Early management is essential to prevent high mortality. A 61-year-old allogeneic stem cell male recipient presented with painful thyroid nodular enlargement. He had low TSH and low free T4 levels. The thyroid ultrasound showed a hypoechoic nodule; biopsy indicated suppurative Aspergillus thyroiditis. He was successfully treated by amphotericin B.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.